Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6529235 | 0.83 | MAPKAPK2 (0.54) | ADORA1ADORA2ARPS6KA3KMT2AMAPKAPK2 | |
| SCHEMBL4396796 | 0.81 | LCK (0.38) | ADORA1ADORA2ALCKKDRJAK3 | |
| Ammonia Solution, Strong SCHEMBL6500596 | 0.79 | QPCT (0.46) | ADORA1ADORA2ALCKKDRJAK3 | |
| Ammonia Solution, Strong SCHEMBL4399088 | 0.76 | ADORA1 (0.48) | ADORA1ADORA2ALCKKDRJAK3 | |
| Ammonia Solution, Strong SCHEMBL4401603 | 0.75 | DYRK1A (0.47) | ADORA1ADORA2ALCKKDRJAK3 | |
| Ammonia Solution, Strong SCHEMBL6496905 | 0.74 | RPS6KA3 (0.46) | ADORA1ADORA2ALCKKDRJAK3 | |
| Ammonia Solution, Strong SCHEMBL6527759 | 0.73 | MAPT (0.46) | ADORA1ADORA2ARPS6KA3KMT2A | |
| Ammonia Solution, Strong SCHEMBL6500606 | 0.72 | KMT2A (0.48) | ADORA1ADORA2ARPS6KA3KMT2ADHFR | |
| SCHEMBL27462618 | 0.68 | POLB (0.35) | MAPKAPK2 | |
| SCHEMBL30494163 | 0.67 | CLK2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | claimed |
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | GSK3B, GSK3A, GSKIP | ADORA1 2287/4885ADORA2A 2203/4885LCK 146/4885 |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | ADORA1 1486/4885ADORA2A 2407/4885LCK 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.